CA2917325C - Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist - Google Patents

Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist Download PDF

Info

Publication number
CA2917325C
CA2917325C CA2917325A CA2917325A CA2917325C CA 2917325 C CA2917325 C CA 2917325C CA 2917325 A CA2917325 A CA 2917325A CA 2917325 A CA2917325 A CA 2917325A CA 2917325 C CA2917325 C CA 2917325C
Authority
CA
Canada
Prior art keywords
endothelin
receptor agonist
irl
brain
etb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2917325A
Other languages
English (en)
French (fr)
Other versions
CA2917325A1 (en
Inventor
Anil Gulati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Midwestern University Glendale
Original Assignee
Midwestern University Glendale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Midwestern University Glendale filed Critical Midwestern University Glendale
Priority to CA3171883A priority Critical patent/CA3171883C/en
Publication of CA2917325A1 publication Critical patent/CA2917325A1/en
Application granted granted Critical
Publication of CA2917325C publication Critical patent/CA2917325C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2917325A 2013-07-08 2014-07-08 Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist Active CA2917325C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3171883A CA3171883C (en) 2013-07-08 2014-07-08 Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361843702P 2013-07-08 2013-07-08
US61/843,702 2013-07-08
US201361902935P 2013-11-12 2013-11-12
US61/902,935 2013-11-12
PCT/US2014/045748 WO2015006324A2 (en) 2013-07-08 2014-07-08 Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3171883A Division CA3171883C (en) 2013-07-08 2014-07-08 Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist

Publications (2)

Publication Number Publication Date
CA2917325A1 CA2917325A1 (en) 2015-01-15
CA2917325C true CA2917325C (en) 2023-09-05

Family

ID=52280704

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2917325A Active CA2917325C (en) 2013-07-08 2014-07-08 Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist
CA3171883A Active CA3171883C (en) 2013-07-08 2014-07-08 Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3171883A Active CA3171883C (en) 2013-07-08 2014-07-08 Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist

Country Status (10)

Country Link
US (2) US10561704B2 (https=)
EP (1) EP3019242B1 (https=)
JP (2) JP6928450B2 (https=)
CN (2) CN113384701A (https=)
AU (1) AU2014287427B2 (https=)
BR (1) BR112016000431A8 (https=)
CA (2) CA2917325C (https=)
ES (1) ES2825101T3 (https=)
PL (1) PL3019242T3 (https=)
WO (1) WO2015006324A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010241564B2 (en) 2009-04-30 2014-07-31 Midwestern University Novel therapeutic treatments using centhaquin
BR112020022395A2 (pt) * 2018-05-03 2021-04-13 Midwestern University Alterações em receptores de endotelina em seguida a hemorragia e ressuscitação por centaquina
US20240207356A1 (en) * 2022-12-26 2024-06-27 Pharmazz, Inc. Composition and method for wound healing and repair of damaged nerves
KR20260005957A (ko) * 2023-04-26 2026-01-12 바이오셀즈(베이징) 바이오테크 코., 엘티디. 폴리펩티드 및 이의 응용
US20250000934A1 (en) 2023-06-28 2025-01-02 Pharmazz, Inc. Lyophilized sovateltide-based injectable formulation and method for preparation thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954987A (en) 1972-12-22 1976-05-04 Sandoz, Inc. 2-Alkyl-4-substituted amino-quinazolines and nitrates thereof in the treatment of myocardial shock
US3983121A (en) 1974-07-01 1976-09-28 Council Of Scientific And Industrial Research 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof
DE2557784C2 (de) 1975-12-22 1986-04-17 Hoechst Ag, 6230 Frankfurt Forskolin, Verfahren zu dessen Gewinnung und diese Verbindung enthaltende pharmazeutische Präparate
US4761417A (en) 1982-05-14 1988-08-02 Maroko Peter R Compounds, compositions and method of treatments for improving circulatory performance
US5055470A (en) 1989-06-01 1991-10-08 Bristol-Myers Squibb Co. Method of treatment of ischemia in brain
US5922681A (en) 1992-09-14 1999-07-13 Warner-Lambert Company Endothelin antagonists
US20040063719A1 (en) 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
SE0004455D0 (sv) 2000-12-01 2000-12-01 Milos Pekny Method for neuron regeneration in the central nervous system
WO2002049630A2 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
US20030232787A1 (en) 2001-05-08 2003-12-18 Dooley David James Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
WO2003009805A2 (en) * 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
US7030082B2 (en) 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US7351692B2 (en) 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
CA2502848C (en) 2002-10-24 2012-10-02 The Board Of Trustees Of The University Of Illinois Use of irl-1620 and paclitaxel for preventing and treating breast tumors
DK1583541T3 (da) 2002-11-20 2011-04-11 Neuronova Ab Forbindelser og fremgangsmåder til at øge neurogenese
WO2008043102A2 (en) 2006-10-06 2008-04-10 Transition Therapeutics Inc. Vasoactive intestinal polypeptide compositions
AU2007230887A1 (en) * 2006-03-23 2007-10-04 Amylin Pharmaceuticals, Inc. Endothelin and endothelin receptor agonists in the treatment of metabolic diseases
PL2182977T4 (pl) 2007-08-21 2017-01-31 Midwestern University Kompozycje do leczenia udaru lub incydentów mózgowo-naczyniowych za pomocą agonisty receptora endoteliny B
CN101374259B (zh) 2007-08-22 2012-08-08 华为技术有限公司 实现多媒体彩铃和多媒体彩像业务的方法和装置
KR101418941B1 (ko) 2011-04-04 2014-07-15 서울대학교병원 엔도텔린을 유효성분으로 함유하는 허혈성질환 치료용 조성물

Also Published As

Publication number Publication date
AU2014287427B2 (en) 2019-11-21
US10561704B2 (en) 2020-02-18
US20160151450A1 (en) 2016-06-02
WO2015006324A2 (en) 2015-01-15
ES2825101T3 (es) 2021-05-14
PL3019242T3 (pl) 2021-02-08
JP2016523969A (ja) 2016-08-12
CN113384701A (zh) 2021-09-14
JP7385924B2 (ja) 2023-11-24
CA3171883C (en) 2024-03-05
BR112016000431A8 (pt) 2018-01-23
CA3171883A1 (en) 2015-01-15
EP3019242A4 (en) 2017-01-25
JP6928450B2 (ja) 2021-09-01
AU2014287427A1 (en) 2016-02-11
JP2021020945A (ja) 2021-02-18
EP3019242B1 (en) 2020-08-19
CN105682741A (zh) 2016-06-15
EP3019242A2 (en) 2016-05-18
US20200353031A1 (en) 2020-11-12
CA2917325A1 (en) 2015-01-15
WO2015006324A3 (en) 2015-11-05
WO2015006324A8 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
JP7385924B2 (ja) エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物
Takagi et al. Temporal activation of Nrf2 in the penumbra and Nrf2 activator-mediated neuroprotection in ischemia–reperfusion injury
Hammerschmidt et al. Selective loss of noradrenaline exacerbates early cognitive dysfunction and synaptic deficits in APP/PS1 mice
US8143221B2 (en) Use of ADNF polypeptides for treating peripheral neurotoxicity
Faivre et al. D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model
Alvarez et al. Ectopic endometrium-derived leptin produces estrogen-dependent chronic pain in a rat model of endometriosis
Pankiewicz et al. APOE genotype differentially modulates effects of anti-Aβ, passive immunization in APP transgenic mice
Leung et al. Microglia activation mediates fibrillar amyloid-β toxicity in the aged primate cortex
US10772827B2 (en) Composition for treating apoplexy through nasal administration
Jellinger et al. Advances in dementia research
GB2571978A (en) Uses, compositions and methods
US11105815B2 (en) Compositions and methods for enhancing neuro-repair
Cantara et al. Opposite effects of beta amyloid on endothelial cell survival: role of fibroblast growth factor-2 (FGF-2)
Hung et al. FGFR1 agonists alleviate pathology and cognitive impairment in an Alzheimer's disease mouse model
You et al. Patchouli alcohol inhibits the NLRP3 inflammasome in microglia to enhance neurogenesis in male mice exposed to chronic mild stress
Yang et al. Investigating the impact of dysregulated brain metabolism on synaptic and cognitive outcomes
Johnson IGF-1-Mediated Reinforcement of the Blood Brain Barrier During Ischemia-reperfusion in Middle-Aged Female Rats
Kirylo Estrogen replacement therapy to reduce neurodegeneration and socio-cognitive deficits in a female Sprague Dawley rat model of early-onset Alzheimer’s disease
Urrutia et al. Inflaming the Brain with Iron. Antioxidants 2021, 10, 61
Urrutia Vargas et al. Inflaming the brain with iron
Mo et al. Patchouli alcohol inhibits the NLRP3 inflammasome in microglia to enhance neurogenesis in male mice exposed to chronic mild stress
Trigiani Benefits of Physical Exercise on Cognitive, White Matter, and Endothelial Dysfunctions in Mouse Models of Vascular Cognitive Impairment and Dementia
Senatorov Mechanisms and treatment of blood-brain barrier dysfunction and related pathology during aging
Brothers Neuroinflammation induces time-dependant behavioral, cellular and molecular changes that resemble characteristics of Alzheimer’s and Parkinson’s diseases and can be modulated by caffeine administration
Sancesario et al. 52nd Congress of the Italian Association of Neuropathology and Clinical Neurobiology (AINPeNC) and 42nd Congress of the Italian Association for Research on Brain Aging (AIRIC) Rome, Italy, May 26-28, 2016

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190704

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250707

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250707